# OnCo record impassion030 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/impassion030/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "impassion030", "NCT03498716" ;
  schema:name "ALEXANDRA / IMpassion030"@en ;
  schema:alternateName "ALEXANDRA"@en, "IMpassion030"@en, "BIG 16-05"@en, "AFT-27"@en ;
  schema:description "ALEXANDRA asked whether a year of the immunotherapy atezolizumab added to chemotherapy after surgery stops triple-negative breast cancer coming back. It did not: relapses were no fewer, side effects were more, and the trial was stopped early for futility."@en ;
  schema:url <https://onco.cc/trials/impassion030/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03498716>, <https://doi.org/10.1001/jama.2024.26886> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/gepardouze/>, <https://onco.cc/trials/a-brave/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/keynote-522/> .